Expression Vectors Market - Growth, Trends, and Forecasts (2022 - 2027)

The expression vectors market is expected to register a CAGR of 5.6% over the forecast period, 2022-2027.

The market has a slightly positive impact due to the pandemic. The development of therapeutic and preventive strategies requires an accurate understanding of the role that proteins play in the SARS-CoV-2 infection process and progression of COVID-19. The vast field of proteomics is well equipped with the technologies needed to help in facing this challenge. In an article published in the Journal of Proteins and Proteomics in October 2020, researchers have highlighted that the developments in proteome technologies will not only accelerate progress in addressing the coronavirus pandemics but could also prove invaluable in tackling the current COVID-19 crisis. According to a report published by Journal of the American College of Cardiology: Basic to Translational Science, on Plasma Proteomics of COVID-19-Associated Cardiovascular Complications, on May 2022, key biological pathways linked to cardiac injury and stress in COVID-19 are identified by plasma proteomics. The von Willebrand factor (VWF)-cleaving protease ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13), whose loss-of-function results in microvascular thrombosis, exhibits the most significant inverse correlation with myocardial damage among the 4,996 analytes examined in COVID-19. The market is expected to gain traction due to the significant increase in the COVID-19 cases globally.

The propelling factors for the growth of the expression vector market include the rise in the R&D activity in the pharmaceutical sector, opportunities in the field of proteomics, and advancements in the biologics market set to boost the market growth and the increasing incidences of lifestyle diseases, infectious diseases and genetic disorders. According to the World Health Organization (WHO) 2021, non-communicable diseases (NCDs) are causative of 41 million deaths yearly, equivalent to 71% of the total death rate. More than 15 million people die each year from non-communicable diseases between 30 and 69 years. About 85% of these "premature" deaths occur in low- and middle-income countries. Also, 77% of all non-communicable disease casualties are in low- and middle-income countries. Cardiovascular diseases account for most non-communicable disease deaths, or 17.9 million fatalities annually, followed by cancers (9.3 million), respiratory diseases (4.1 million), and diabetes (1.5 million). These growing cases of non-communicable diseases are expected to further increase the demand for biologics in treating chronic diseases. Biologics have played a crucial role in the treatment process of many health issues. The growing demand for biologicals increases the prospects of its manufacturing using the expression vector systems, thus, boosting the market growth.

Therefore, the factors mentioned above are attributed collectively to the studied market growth over the forecast period. However high cost of protein expression systems is expected to hinder the market growth over the forecast period.

Key Market Trends

Bacterial expression vectors are Expected to Witness High Growth Over the Forecast Period

Bacterial expression vectors are DNA molecules that are used to transfer foreign genetic material into a host in order to replicate and amplify the foreign DNA sequences as a recombinant molecule. Bacterial expression vectors are found to hold the largest share which can be attributed to the increasing the prevalence of cancer and infectious diseases and focus areas for many companies in the bacterial and plasmid vectors. Recombinant proteins are delivered into target cells using bacteria as a carrier for the treatment of cancer and a number of infectious disorders. The World Health Organization (WHO) reports that cancer is the second biggest cause of death in the world. In 2020, there were 19.3 million new cases of cancer worldwide, and in 2040, there are expected to be 28.4 million new cases. Additionally, the WHO reports that there are numerous dangers to public health around the world, ranging from climate change to a lack of adequate healthcare facilities, with infectious diseases dominating the WHO's list of health hazards for 2019. Such increase in cancer cases boosting the segment growth.

Many companies shifted to increase mergers and acquisitions to acquire more production capabilities. For instance, Thermo Fisher Scientific launched viral vector manufacturing facility in Plainville, Massachusetts, in August 2022, expanding its capabilities in cell and gene therapy. Also in February 2021, Catalent acquired Delphi Genetics and opened a US plasmid manufacturing facility to establish global pDNA development and manufacturing capabilities. Such increasing in development in the segment is further enhancing the growth in the forecast period.

North America is Expected to Dominate the Expression Vectors Market

North America is the largest market for expression vector and is expected to dominate the overall expression vector market due to factors like the presence of well-established healthcare infrastructure in these regions combined with the intense R&D activities carried out. The US expression vector market is driven by factors, such as an increase in the usage of protein technologies, the rapid evolution of the pharmaceutical industry in the region, and investment of government and private companies in synthetic biology research in the region itself.

According to the report of the American Cancer Society, published in January 2021, there is an estimated 1,898,160 new cases of cancer, and 608,570 people died from it. The increasing demand and acceptance of gene and monoclonal antibody-based therapies in the treatment of diseases such as cancer, rare diseases, and other disorders and investment in R&D are driving the growth of the expression vector market in the region.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region

Competitive Landscape

The expression vectors market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known include Thermo Fisher Scientific, Inc., Promega Corporation, Sigma-Aldrich Corporation, Bio-Rad Laboratories, Agilent Technologies, New England Biolabs, Merck KGaA, TAKARA HOLDINGS Inc., QIAGEN, DNA2.0, and GenScript USA Inc., among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support